CardioDynamics International and Spacelabs Medical Announce Technology Development Agreement

BioZ ICG Technology to Be Integrated With Spacelabs Patient Monitors



Apr 23, 2001, 01:00 ET from CardioDynamics International Corporation from ,Spacelabs Medical, Inc.

    REDMOND, Wash. and SAN DIEGO, April 23 /PRNewswire Interactive News
 Release/ -- Spacelabs Medical, Inc. (Nasdaq: SLMD), a leading provider of
 integrated medical information systems and instrumentation, and CardioDynamics
 International Corporation (Nasdaq: CDIC), the innovator and market leader in
 Impedance Cardiography (ICG), today announced an agreement to develop a
 Universal Flexport(R) interface to integrate CardioDynamics' ICG technology
 with Spacelabs Ultraview Care Network(TM) monitoring system.  This development
 will allow BioZ's noninvasive ICG measurements (cardiac output, stroke volume,
 systemic vascular resistance, and fluid status) to be displayed on Spacelabs'
 monitors.
     "We are pleased to partner and build strategic relationships with medical
 device companies, such as Spacelabs, to provide our noninvasive ICG
 measurements to the critical care market," stated Michael K. Perry, CEO of
 CardioDynamics.  "A key element of our business strategy is to establish long-
 term partnerships with leading companies whose interests are complimentary to
 ours.  Integrating our proprietary ICG technology with Spacelabs monitoring
 systems will help us to accelerate penetration of the estimated $2 billion
 noninvasive hemodynamic monitoring hospital market.  Our strategic
 partnerships are driving ICG technology towards becoming the Sixth Vital Sign
 for patient monitoring."
     With the Universal Flexport interface, vital ICG patient data is
 integrated on a single screen to provide comprehensive information to the
 clinician.  In addition to having ICG data displayed on the patient's bedside
 monitor, the data also becomes an integral part of the monitoring system and
 can be communicated over the network to other locations and included in the
 facility's clinical information systems.
     Commenting on the partnership, Roy Hays, vice president of product
 development for Spacelabs, stated, "The strategic alliance between our two
 companies is right in line with the demands of today's critical care
 environment.  Our Flexport system interfaces now integrate data from more than
 90 different third-party peripheral devices.  Hospitals benefit from
 tremendous flexibility and cost savings, allowing them to integrate new
 standalone devices as they become available."
 
     About Spacelabs Medical:
     Spacelabs is a leading provider of integrated medical information systems
 and instrumentation with a strategic focus on wireless, telemedicine and
 Internet solutions for healthcare.  For more information about Spacelabs,
 please visit www.spacelabs.com.
 
     About CardioDynamics:
     CardioDynamics, with headquarters in San Diego, is a medical technology
 and information solutions company committed to fundamentally changing the way
 hemodynamic monitoring is performed in healthcare.  The Company's primary
 products, the BioZ(R) Systems, utilize proprietary BioZ Impedance Cardiography
 (ICG) technology to noninvasively provide medical professionals with
 hemodynamic data not previously available in the physician's office and many
 hospital settings.  Just as electrocardiography (ECG) measures the heart's
 electrical characteristics, ICG makes it possible to noninvasively measure the
 heart's mechanical (blood flow) characteristics.  Physicians around the world
 are currently using the BioZ products, including major medical centers such as
 the Mayo Clinic (Rochester), Stanford University School of Medicine (Palo
 Alto), University of California San Francisco (San Francisco), Yale New Haven
 Hospital (New Haven) and Baylor College of Medicine (Houston).  The worldwide
 market potential for BioZ products is estimated to be $5 billion, together
 with an additional $800 million in recurring annual revenue for disposables.
 For additional information, please refer to the company's Web site at
 www.cdic.com.
 
     Forward-Looking (Safe Harbor) Statement
     Note: Except for the historical and factual information contained herein,
 this press release contains forward-looking statements, the accuracy of which
 are necessarily subject to uncertainties and risks, which include sole
 dependence on the BioZ product line, competition from Edwards Lifesciences
 (manufacturer of the Swan-Ganz(R) device), and various uncertainties
 characteristic of companies just emerging from the development stage, as well
 as other risks detailed in the company's filings with the SEC, including its
 2000 Form 10-KSB.  The company does not undertake to update the disclosures
 contained in this press release.
 
     Flexport is a trademark of Spacelabs Medical, Inc.
     BioZ is a trademark of CardioDynamics International Corporation.
 
     For further information please contact Bonnie Dupuis, Investor Relations,
 ext. 1005, bdupuis@cdic.com, or Irene Paigah, Media Relations, ext. 1012,
 ipaigah@cardiodynamics.com, both of CardioDynamics International,
 800-778-4825; or investors, Clark Thompson, 425-867-7345, or media, Karyn
 Beckley, 425-882-3753, both of Spacelabs Medical, Inc.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X44748384
 
 

SOURCE CardioDynamics International Corporation; Spacelabs Medical, Inc.
    REDMOND, Wash. and SAN DIEGO, April 23 /PRNewswire Interactive News
 Release/ -- Spacelabs Medical, Inc. (Nasdaq: SLMD), a leading provider of
 integrated medical information systems and instrumentation, and CardioDynamics
 International Corporation (Nasdaq: CDIC), the innovator and market leader in
 Impedance Cardiography (ICG), today announced an agreement to develop a
 Universal Flexport(R) interface to integrate CardioDynamics' ICG technology
 with Spacelabs Ultraview Care Network(TM) monitoring system.  This development
 will allow BioZ's noninvasive ICG measurements (cardiac output, stroke volume,
 systemic vascular resistance, and fluid status) to be displayed on Spacelabs'
 monitors.
     "We are pleased to partner and build strategic relationships with medical
 device companies, such as Spacelabs, to provide our noninvasive ICG
 measurements to the critical care market," stated Michael K. Perry, CEO of
 CardioDynamics.  "A key element of our business strategy is to establish long-
 term partnerships with leading companies whose interests are complimentary to
 ours.  Integrating our proprietary ICG technology with Spacelabs monitoring
 systems will help us to accelerate penetration of the estimated $2 billion
 noninvasive hemodynamic monitoring hospital market.  Our strategic
 partnerships are driving ICG technology towards becoming the Sixth Vital Sign
 for patient monitoring."
     With the Universal Flexport interface, vital ICG patient data is
 integrated on a single screen to provide comprehensive information to the
 clinician.  In addition to having ICG data displayed on the patient's bedside
 monitor, the data also becomes an integral part of the monitoring system and
 can be communicated over the network to other locations and included in the
 facility's clinical information systems.
     Commenting on the partnership, Roy Hays, vice president of product
 development for Spacelabs, stated, "The strategic alliance between our two
 companies is right in line with the demands of today's critical care
 environment.  Our Flexport system interfaces now integrate data from more than
 90 different third-party peripheral devices.  Hospitals benefit from
 tremendous flexibility and cost savings, allowing them to integrate new
 standalone devices as they become available."
 
     About Spacelabs Medical:
     Spacelabs is a leading provider of integrated medical information systems
 and instrumentation with a strategic focus on wireless, telemedicine and
 Internet solutions for healthcare.  For more information about Spacelabs,
 please visit www.spacelabs.com.
 
     About CardioDynamics:
     CardioDynamics, with headquarters in San Diego, is a medical technology
 and information solutions company committed to fundamentally changing the way
 hemodynamic monitoring is performed in healthcare.  The Company's primary
 products, the BioZ(R) Systems, utilize proprietary BioZ Impedance Cardiography
 (ICG) technology to noninvasively provide medical professionals with
 hemodynamic data not previously available in the physician's office and many
 hospital settings.  Just as electrocardiography (ECG) measures the heart's
 electrical characteristics, ICG makes it possible to noninvasively measure the
 heart's mechanical (blood flow) characteristics.  Physicians around the world
 are currently using the BioZ products, including major medical centers such as
 the Mayo Clinic (Rochester), Stanford University School of Medicine (Palo
 Alto), University of California San Francisco (San Francisco), Yale New Haven
 Hospital (New Haven) and Baylor College of Medicine (Houston).  The worldwide
 market potential for BioZ products is estimated to be $5 billion, together
 with an additional $800 million in recurring annual revenue for disposables.
 For additional information, please refer to the company's Web site at
 www.cdic.com.
 
     Forward-Looking (Safe Harbor) Statement
     Note: Except for the historical and factual information contained herein,
 this press release contains forward-looking statements, the accuracy of which
 are necessarily subject to uncertainties and risks, which include sole
 dependence on the BioZ product line, competition from Edwards Lifesciences
 (manufacturer of the Swan-Ganz(R) device), and various uncertainties
 characteristic of companies just emerging from the development stage, as well
 as other risks detailed in the company's filings with the SEC, including its
 2000 Form 10-KSB.  The company does not undertake to update the disclosures
 contained in this press release.
 
     Flexport is a trademark of Spacelabs Medical, Inc.
     BioZ is a trademark of CardioDynamics International Corporation.
 
     For further information please contact Bonnie Dupuis, Investor Relations,
 ext. 1005, bdupuis@cdic.com, or Irene Paigah, Media Relations, ext. 1012,
 ipaigah@cardiodynamics.com, both of CardioDynamics International,
 800-778-4825; or investors, Clark Thompson, 425-867-7345, or media, Karyn
 Beckley, 425-882-3753, both of Spacelabs Medical, Inc.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X44748384
 
 SOURCE  CardioDynamics International Corporation; Spacelabs Medical, Inc.